You are here

BioFulcrum

Even within the finest academic institutions, scientists are not yet capturing the full power of emerging technology, computational methods, and new biological insights in a timely manner. Gladstone leadership, with its history of taking uncommon scientific paths to overcome deadly diseases, both in terms of research programs and organizational models, sought a solution to this important issue.

As a result, BioFulcrum was launched in January 2015 as an entrepreneurial model within Gladstone. The goal of BioFulcrum is to accelerate the discovery of cures for major unsolved diseases by converging scientists, multiple non-profit institutions, and industry partners.

The Science

The Model

BioFulcrum’s operating model is founded on team science, bringing together new research technologies and scientific partners from multiple San Francisco Bay Area institutions to conduct research that exceeds the capacity of any single lab. It operates as a project-centric innovation group and leverages combined expertise in diverse scientific disciplines and techniques in order to create more compelling biological evidence for new therapeutic avenues.

BioFulcrum blends the best features of academic creativity and social mission with the discipline and focus of commercial enterprise. Its projects are translation-focused and milestone-driven, and academic or commercial partners are strategically implemented as appropriate.

BioFulcrum will continue to continue to expand with new industry partners, academic partners, and philanthropic support. And unlike traditional academic endeavors, its success will not be measured by publishable units, but by achieving objectives defined as essential for the realization of clinical goals.

Competitive Advantage

  • Experienced cross-disciplinary scientific teams drawn from Gladstone and its partners in the San Francisco Bay Area, including UC San Francisco and Stanford
  • Milestone-driven scientific goals
  • Strategic and tactical plans guided by a board with industry and biotech venture experience
  • New organizational model with incentives that support team science

Executive Leadership

Sandy Williams, MD, CEO

Deepak Srivastava, MD, Lead Partner, Heart Failure Program

Melanie Ott, PhD, Lead Partner, Viral and Infectious Disease Program

Nevan Krogan, PhD, Lead Partner, Viral and Infectious Disease Program

Strategic Priorities Board

Ian Clark

Brian Daniels, MD

David Goeddel, PhD

Perry Karsen

Bill Price

Bill Rutter, PhD

Elliott Sigal, MD, PhD

Deepak Srivastava, MD

Virginia Tusher, PhD

Sandy Williams, MD